61 related articles for article (PubMed ID: 9629542)
1. [Heparin-induced type II thrombocytopenia within the scope of high dose chemotherapy with subsequent stem cell rescue].
Sauer M; Gruhn B; Fuchs D; Altermann W; Zintl F
Klin Padiatr; 1998; 210(3):102-5. PubMed ID: 9629542
[TBL] [Abstract][Full Text] [Related]
2. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Dworschak M; Hiesmayr JM; Lassnigg A
Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
[TBL] [Abstract][Full Text] [Related]
3. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C
Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522
[TBL] [Abstract][Full Text] [Related]
5. [Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
Herzog S; Rath W; Kuhn W
Geburtshilfe Frauenheilkd; 1995 Mar; 55(3):164-6. PubMed ID: 7665065
[TBL] [Abstract][Full Text] [Related]
6. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
7. [Current treatment concepts in heparin-induced thrombocytopenia].
Ranze O; Greinacher A
Dtsch Med Wochenschr; 1999 Jul; 124(28-29):865-73. PubMed ID: 10432950
[No Abstract] [Full Text] [Related]
8. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Aouifi A; Blanc P; Piriou V; Bastien OH; Ffrench P; Hanss M; Lehot JJ
Ann Thorac Surg; 2001 Feb; 71(2):678-83. PubMed ID: 11235727
[TBL] [Abstract][Full Text] [Related]
9. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
[TBL] [Abstract][Full Text] [Related]
10. The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.
Hertle DN; Hähnel S; Richter GM; Unterberg A; Sakowitz OW; Kiening KL
Br J Neurosurg; 2011 Feb; 25(1):117-9. PubMed ID: 20707682
[TBL] [Abstract][Full Text] [Related]
11. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).
Gerhardt A; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630
[TBL] [Abstract][Full Text] [Related]
12. A case of heparin-induced thrombocytopenia with repeated episodes of acute lower extremity arterial thromboembolism during a short time.
Masumoto H; Shimamoto M; Yamazaki F; Nakai M; Fujita S; Itonaga T; Nomura R
Ann Thorac Cardiovasc Surg; 2007 Oct; 13(5):365-7. PubMed ID: 17954999
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
[TBL] [Abstract][Full Text] [Related]
14. [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation].
Scheffler E; Aulmann M; Remppis A; Ziegler R; Martin E; Fleischer F; Nawroth P
Z Kardiol; 1995 Jul; 84(7):565-8. PubMed ID: 7676727
[TBL] [Abstract][Full Text] [Related]
15. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
Ben Ami R; Rachmimov R; Berliner S
Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
[TBL] [Abstract][Full Text] [Related]
16. [Loss of extremities caused by heparin-induced thrombocytopenia].
Wenzl ME; Leffringhausen W; Scherlitzky L
Unfallchirurg; 1996 Aug; 99(8):607-11. PubMed ID: 8975383
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation in patients with heparin-induced thrombocytopenia type II.
Harenberg J; Huhle G; Piazolo L; Wang LU; Heene DL
Semin Thromb Hemost; 1997; 23(2):189-96. PubMed ID: 9200346
[TBL] [Abstract][Full Text] [Related]
18. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
[TBL] [Abstract][Full Text] [Related]
19. [Heparin-induced thrombocytopenia--a serious complication within the scope of heparin therapy. Follow-up of 7 trauma surgery patients].
Kuhn B
Unfallchirurg; 1997 Aug; 100(8):646-51. PubMed ID: 9381213
[TBL] [Abstract][Full Text] [Related]
20. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
Lindhoff-Last E; Betz C; Bauersachs R
Clin Appl Thromb Hemost; 2001 Oct; 7(4):300-4. PubMed ID: 11697713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
